PuraMed Bioscience has announced the filing of its first US patent application that centers around the unique lipid-based formulation of its migraine headache relief product.
Subscribe to our email newsletter
The granting of this patent is expected to provide protection in the US as well as in major markets internationally.
Russell Mitchell, CEO of PuraMed Bioscience, said: “The filing of our initial patent is the first of many steps in our efforts to build a strong intellectual property portfolio. A strong IP portfolio will provide us with the necessary protection as we introduce our products to the marketplace as well as increasing long-term shareholder value.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.